Switching of transcriptional control from interferon regulatory factor 2 to interferon regulatory factor 1 drives innate immune cell activation
Cell · 2026
DOI: 10.1016/j.cell.2026.08.049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2026. Verfasst von Cristhian Cadena und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA. Hauptthemen laut MEDLINE: Interferon Regulatory Factor-2, Interferon Regulatory Factor-1, Immunity, Innate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genentech Inc.
Abstract (Originalsprache)
Interferon regulatory factor 2 (IRF2) is a transcription factor that prevents skin inflammation in mice and humans but, paradoxically, promotes pyroptosis by upregulating gasdermin D. How IRF2 activates some proinflammatory genes but suppresses inflammation is unclear. We show that skin inflammation in Irf2-deficient mice is driven by IRF1 activation of interferon-stimulated genes (ISGs). Chromatin profiling reveals that IRF1 and IRF2 occupy the same ISG regulatory sites, but as a weaker transcriptional activator, IRF2 limits ISG transcription by IRF1. Toll-like receptor (TLR) signaling favors IRF1-driven transcription by inducing Irf1. In addition, IRF1 recruits the ubiquitin ligase SPOP to ISG sites, resulting in proteasomal degradation of IRF2. This shift from IRF2 to IRF1 occupancy enhances ISG transcription. Collectively, these findings define a hierarchical transcriptional circuit in which IRF2 limits IRF1 activity under homeostatic conditions but is displaced during an immune response, allowing IRF1-dependent gene programs central to innate immunity and autoinflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA.
- Department of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA; Department of Computational Sciences, Genentech, South San Francisco, CA 94080, USA.
- Department of Pathology, Genentech, South San Francisco, CA 94080, USA.
- Department of Proteomic and Genomic Technologies, Genentech, South San Francisco, CA 94080, USA.
- Department of Antibody Engineering, Genentech, South San Francisco, CA 94080, USA.
- Princess Margaret Cancer Center, University Health Network, Toronto, ON, M5G2M9, Canada; Department of Immunology, University of Toronto, Toronto, ON, M5S1A8, Canada.
Förderung
- Genentech Inc
Zitieren
APA
Cadena, C., Reja, R., Bolech, E., Webster, J. D., Kameswaran, V., de Simone, M., Chen, C., Jiang, J., Hotzel, K., Bjornson, C., Alegre, K., Tan, Z., Elsaesser, H. J., Newland, R., Kelly, R., Darmanis, S., Daniel, B., Brooks, D. G., Deshpande, I., …, & Dixit, V. M. (2026). Switching of transcriptional control from interferon regulatory factor 2 to interferon regulatory factor 1 drives innate immune cell activation. Cell. https://doi.org/10.1016/j.cell.2026.08.049
Vancouver
Cadena C, Reja R, Bolech E, Webster JD, Kameswaran V, de Simone M, et al. Switching of transcriptional control from interferon regulatory factor 2 to interferon regulatory factor 1 drives innate immune cell activation. Cell. 2026. doi:10.1016/j.cell.2026.08.049
BibTeX
@article{Cadena2026,
author = {Cadena, Cristhian and Reja, Rohit and Bolech, Emma and Webster, Joshua D and Kameswaran, Vasumathi and de Simone, Marco and Chen, Cynthia and Jiang, Jian and Hotzel, Kathy and Bjornson, Christopher and Alegre, Kamela and Tan, Zhenyu and Elsaesser, Heidi J and Newland, Raymond and Kelly, Ryan and Darmanis, Spyros and Daniel, Bence and Brooks, David G and Deshpande, Ishan and Newton, Kim and Kayagaki, Nobuhiko and Dixit, Vishva M},
title = {Switching of transcriptional control from interferon regulatory factor 2 to interferon regulatory factor 1 drives innate immune cell activation},
journal = {Cell},
year = {2026},
doi = {10.1016/j.cell.2026.08.049}
}
EUVIMED